ZHANG, JIAZHONG,BREMER, RYAN,SPEVAK, WAYNE,CHO, HANNA,IBRAHIM, PRABHA N.
申请号：
PE2012000617
公开号：
PE20121327A1
申请日:
2010.11.04
申请国别(地区):
PE
年份:
2012
代理人:
摘要：
The compound refers to pyridine (I) derivative [2,3-b] pyridine (I), wherein R1, R2, R3 and R4 are h, halogenated, low tar, cyclopropene, etc.； R5 is h, F, Cl, low tar, pyridinol, CN, etc.； R6 is h, halogenated, cyclopropylsulfone, phenyl, pyridinediene, etc.； AR is a formula compound (I),Page: 1(III)Among them, R7 is h, halogen or low carbon； R9 is h or halogen. , 3 -, long and long-lasting two -, long and long-lasting two -, long and long-lasting two -, long and long-lasting two -, long and long-lasting two -, long and long-lasting six - [(5-fluoro-2-methoxi-piridin-3-lumey) - amine] - piridin-3-lumeh} - 1H pirrolo [2, 3 (b) pyridine-5-il-acetamide, etc. He also mentioned a pharmaceutical composer These compounds are inhibitors of FMS, kit and ft-3 and can be used in the treatment of multiple sclerosis, rheumatoid arthritis, lupus erythematosus and systemic lupus.cocciSE REFIERE A COMPUESTOS DERIVADOS DE PIRROLO[2,3-b]PIRIDIN DE FORMULA (I) DONDE R1, R2, R3 Y R4 SON CADA UNO H, HALOGENO, ALQUILO INFERIOR, CICLOALQUILAMINO, ENTRE OTROS； R5 ES H, F, Cl, ALQUILO INFERIOR, PIRAZOLILO, CN, ENTRE OTROS； R6 ES H, HALOGENO, CICLOALQUILO, FENILO, PIRAZOLILO, ENTRE OTROS； Ar ES UN COMPUESTO DE FORMULA (i), (ii), (iii), ENTRE OTROS, EN DONDE R7 ES H, HALOGENO O ALQUILO INFERIOR； R9 ES H O HALOGENO. SON COMPUESTOS PREFERIDOS: [5-(5-CLORO-1H-PIRROLO[2,3-b]PIRIDIN-3-ILMETIL)-PIRIDIN-2-IL]-(2,6-DIMETOXI-PIRIDIN-3-ILMETIL)-AMINA； N-(3-{6-[(6-CLORO-PIRIDIN-3-ILMETIL)-AMINO]-2-FLUORO-PIRIDIN-3-ILMETIL}-1H-PIRROLO[2,3-b]PIRIDIN-5-IL)-METANOSULFONAMIDA； N-(3-{2-FLUORO-6-[(5-FLUORO-2-METOXI-PIRIDIN-3-ILMETIL)-AMINO]-PIRIDIN-3-ILMETIL}-1H-PIRROLO[2,3-b]PIRIDIN-5-IL)-ACETAMIDA； ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE CINASAS Fms, Kit Y Flt-3 SIENDO UTILES EN EL TRATAMIENTO DE ESCLEROSIS MULTIPLE, ARTRITIS REUMATOIDE, LUPUS ERITEMATOSO SISTEMICO, GLOMERULONEFRITIS
